Biotech Fundraising: Attracting Corporate Partners in 2026
Biotech needs corporate funding. Learn how to attract strategic partners with de-risked assets, clear regulatory paths, and early engagement.
Biotech needs corporate funding. Learn how to attract strategic partners with de-risked assets, clear regulatory paths, and early engagement.
Ohio VC funding hit $1.5B in 2025. Founders: see how state programs like Third Frontier and new accelerators boost your startup's chances.
Accelevation's Nasdaq IPO beat 0.09% odds. See their $1.5M seed round to $1.2B valuation journey and key lessons for tech startups.
US dollar strength in 2026 impacts founders' investments. Learn how to adapt strategies, manage cash flow, and find growth in a strong dollar economy.
Accelevation's 2026 IPO could change tech financing. See how growth equity, AI, and global expansion de-risk its path to public markets.
Accelevation's new IPO blueprint challenges traditional startup growth. See how their 5-7 year plan aims to de-risk going public.
How will the strong US dollar in 2026 impact AI investment? Learn why currency dynamics are reshaping global capital flows for venture capitalists.
New funding and $18 billion in private capital are boosting defense tech. See how this impacts military readiness and what's next.
VC funding shifts: startups need clear profit paths, 1:3 CAC to LTV, and strong financial models by 2026. See what investors prioritize now.
Can BioSynth Dynamics secure Series A in Ohio's VC scene? Learn why Columbus biotech startups need $5M+ investment strategies. 2025 funding hit $3.1B.